Novel antiviral drug concept targets number of human viruses

In laboratory studies, an entirely new approach to antiviral drug development is showing remarkable effectiveness against herpes viruses, a large family of viruses associated with many human diseases. In addition, the innovative strategy targets these viruses at such a fundamental level that it may prove useful against a wide array of other viruses. And because the approach attacks viruses indirectly by making the cells they infect profoundly inhospitable to them, the likelihood that viral drug resistance will develop is thought to be extremely low.

University of Pennsylvania Medical Center researchers reported the findings in a study presented today at the Thirteenth International Conference on Antiviral Research in Baltimore, MD.

"This is a novel approach to the development of antiviral drugs," says Luis M. Schang, Ph.D., a postdoctoral fellow and first author on the study. "In the laboratory, we and others are seeing significant viral inhibition with drugs that have no toxicity to cells. If the strategy shows similar success in animals and, eventually, in humans, it should be applicable against many different kinds of viral infections."

Schang emphasizes that a good deal of work remains to be done before the new approach can be validated as a viable treatment for viral infections in humans.

Until now, antiviral drugs have sought to attack viruses directly by interfering with essential proteins produced by the viruses. Scientists have long known, however, that viruses are parasites and depend on the cells they infect for crucial support of their life cycles. Using the herpes simplex virus (HSV) as model target, the Penn team discovered that by inhibiting a particular set of cellular enzymes upon which the virus depends they can successfully block all viral activity while causing the host cells no ill effects.

"To date, all effective anti-viral drugs target viral proteins because the thought has been that knocking out a cellular

Contact: Franklin Hoke
University of Pennsylvania School of Medicine

Page: 1 2 3

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:5/9/2019)... (PRWEB) , ... May 09, 2019 , ... ... of its first suite of products based on its microbubble technology. Unlike magnetic-based ... simply float to the surface. Feedback from customers who participated in an early ...
(Date:5/8/2019)... , ... May 08, 2019 , ... ... Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services that ... trials and observational studies. Axiom is a leading e-clinical technology company that focuses ...
(Date:5/2/2019)... ... April 30, 2019 , ... Philadelphia intellectual property law firm ... Gunes Bender, Ph.D., a registered patent agent, has joined the firm as a ... Bender provides technical support and scientific expertise in the pharmaceutical and biotechnical arts ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... ... May 03, 2019 , ... ... the Diopsys® ffERG/Photopic Negative Response vision test, a new full field ... it is estimated that 6.3 million Americans will have glaucoma, with black Americans ...
(Date:5/2/2019)... ... May 02, 2019 , ... Researchers ... present results documenting discrepancies between U.S. insurer policies for genetic testing and the ... for hereditary breast and ovarian cancer (HBOC). , Jill S. Dolinsky, ...
(Date:4/18/2019)... Mass. (PRWEB) , ... April 18, 2019 , ... ... fossil fuels, a research team that includes a chemical engineer at Worcester Polytechnic ... exotic microorganism that may make it possible to manufacture isobutanol and other biofuels ...
(Date:4/12/2019)... JUPITER, Fla. (PRWEB) , ... April 12, 2019 ... ... will explore recent developments in neurotechnology and will educate about innovative tools and ... 3Q/2019. Check your local listings for more information. , This segment of Advancements ...
Breaking Biology Technology:
Cached News: